Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study

References

• Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. doi:10.1038/nrdp.2016.5727510637
   PubMed Web of Science ®Google Scholar
• Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687–708. doi:10.1093/humupd/dmw02527511809
   PubMed Web of Science ®Google Scholar
• Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23(3):462–477. doi:10.1093/humrep/dem42618308833
   PubMed Web of Science ®Google Scholar
• Reichman DE, Zakarin L, Chao K, Meyer L, Davis OK, Rosenwaks Z. Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertil Steril. 2014;102(1):99–102. doi:10.1016/j.fertnstert.2014.04.01024882557
   PubMed Web of Science ®Google Scholar
• Bosch E, Valencia I, Escudero E, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril. 2003;80(6):1444–1449. doi:10.1016/j.fertnstert.2003.07.00214667881
   PubMed Web of Science ®Google Scholar
• Sterling L, Liu J, Okun N, Sakhuja A, Sierra S, Greenblatt E. Pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization. Fertil Steril. 2016;105(3):791–797. doi:10.1016/j.fertnstert.2015.11.01926654973
   PubMed Web of Science ®Google Scholar
• Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104(1):62–70. doi:10.1016/j.fertnstert.2015.03.02225956370
   PubMed Web of Science ®Google Scholar
• Harris TG, Dye S, Robinson JE, Skinner DC, Evans NP. Progesterone can block transmission of the estradiol-induced signal for luteinizing hormone surge generation during a specific period of time immediately after activation of the gonadotropin-releasing hormone surge-generating system. Endocrinology. 1999;140(2):827–834. doi:10.1210/endo.140.2.64909927312
   PubMed Web of Science ®Google Scholar
• Wildt L, Hutchison JS, Marshall G, Pohl CR, Knobil E. On the site of action of progesterone in the blockade of the estradiol-induced gonadotropin discharge in the rhesus monkey. Endocrinology. 1981;109(4):1293–1294. doi:10.1210/endo-109-4-12936793348
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y. Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial. Medicine (Baltimore). 2016;95(9):e2939. doi:10.1097/MD.000000000000293926945402
   PubMed Web of Science ®Google Scholar
• Guo H, Wang Y, Chen Q, et al. Use of medroxyprogesterone acetate in women with ovarian endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization. Sci Rep. 2017;7(1):11927. doi:10.1038/s41598-017-12151-728931865
   PubMed Web of Science ®Google Scholar
• Lu X, Hong Q, Sun L, et al. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist. Fertil Steril. 2016;106(6):1356–1362. doi:10.1016/j.fertnstert.2016.07.106827490046
   PubMed Web of Science ®Google Scholar
• Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33(2):229–237.29300975
   PubMed Web of Science ®Google Scholar
• Chen ZJ, Shi Y, Sun Y, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med. 2016;375(6):523–533. doi:10.1056/NEJMoa151387327509101
   PubMed Web of Science ®Google Scholar
• Shi Y, Sun Y, Hao C, et al. Transfer of fresh versus frozen embryos in ovulatory women. N Engl J Med. 2018;378(2):126–136. doi:10.1056/NEJMoa170533429320646
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. doi:10.1016/j.fertnstert.2003.10.004
   Web of Science ®Google Scholar
• Huang J, Lin J, Gao H, et al. Anti-mullerian hormone for the prediction of ovarian response in progestin-primed ovarian stimulation protocol for IVF. Front Endocrinol (Lausanne). 2019;10:325.31191453
   PubMed Web of Science ®Google Scholar
• Cummins JM, Breen TM, Harrison KL, Shaw JM, Wilson LM, Hennessey JF. A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. J in vitro Fert Embryo Transf. 1986;3(5):284–295. doi:10.1007/BF01133388
   PubMedGoogle Scholar
• Gardner DK, Schoolcraft WB. In vitro culture of human blastocyst In: Jansen R, Mortimer D, editors. Towards Reproductive Certainty: Infertility and Genetics Beyond 1999. Carnforth: Parthenon Press; 1999:378–388.
   Google Scholar
• Larue L, Keromnes G, Massari A, et al. Transvaginal ultrasound-guided embryo transfer in IVF. J Gynecol Obstet Hum Reprod. 2017;46(5):411–416. doi:10.1016/j.jogoh.2017.02.01528428123
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Vitagliano A, Di Giovanni MV, et al. Ultrasound-guided embryo transfer: summary of the evidence and new perspectives. A systematic review and meta-analysis. Reprod Biomed Online. 2018;36(5):524–542. doi:10.1016/j.rbmo.2018.01.01529576332
   PubMed Web of Science ®Google Scholar
• Chen H, Wang Y, Lyu Q, et al. Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles. Fertil Steril. 2015;103(5):1194–1201. doi:10.1016/j.fertnstert.2015.02.02025813280
   PubMed Web of Science ®Google Scholar
• Zhang J, Mao X, Wang Y, et al. Neonatal outcomes and congenital malformations in children born after human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles. Arch Gynecol Obstet. 2017;296(6):1207–1217. doi:10.1007/s00404-017-4537-z28948397
   PubMed Web of Science ®Google Scholar
• Huang J, Xie Q, Lin J, et al. Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Des Devel Ther. 2019;13:2553–2563. doi:10.2147/DDDT.S210228
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen Q, Yu S, et al. Progestin-primed ovarian stimulation with or without clomiphene citrate supplementation in normal ovulatory women undergoing in vitro fertilization/intracytoplasmic sperm injection: a prospective randomized controlled trial. Clin Endocrinol (Oxf). 2018;88(3):442–452. doi:10.1111/cen.2018.88.issue-329247457
   PubMed Web of Science ®Google Scholar
• Practice Committee of American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106(7):1634–1647. doi:10.1016/j.fertnstert.2016.08.04827678032
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl 1):S7–S16. doi:10.1016/j.maturitas.2003.09.01414670641
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34(2):171–208. doi:10.1210/er.2012-100823238854
   PubMed Web of Science ®Google Scholar
• Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of cochrane reviews. Cochrane Database Syst Rev. 2017;1:Cd012103.28111738
   PubMed Web of Science ®Google Scholar
• Griesinger G, Tournaye H, Macklon N, et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2018.
   Web of Science ®Google Scholar
• Tournaye H, Sukhikh GT, Kahler E, Griesinger G, Phase A. III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017;32(5):1019–1027. doi:10.1093/humrep/dex02328333318
   PubMed Web of Science ®Google Scholar
• Griesinger G, Blockeel C, Sukhikh GT, et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018;33(12):2212–2221.30304457
   PubMed Web of Science ®Google Scholar
• Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59(5):437–447. doi:10.1016/j.jclinepi.2005.07.00416632131
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.56878621818162
   PubMed Web of Science ®Google Scholar
• Fischer D, Reisenbuchler C, Rosner S, Haussmann J, Wimberger P, Goeckenjan M. Avoiding OHSS: controlled ovarian low-dose stimulation in women with PCOS. Geburtshilfe Frauenheilkd. 2016;76(6):718–726. doi:10.1055/s-0000002027365543
   PubMed Web of Science ®Google Scholar
• Di Paola R, Garzon S, Giuliani S, et al. Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman’s age and markers of ovarian reserve. Arch Gynecol Obstet. 2018;298(5):1029–1035. doi:10.1007/s00404-018-4906-230242498
   PubMed Web of Science ®Google Scholar
• Broekmans FJ. Individualization of FSH doses in assisted reproduction: facts and fiction. Front Endocrinol (Lausanne). 2019;10:181.31080437
   PubMed Web of Science ®Google Scholar